Staci Martin

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Terry J. Fry, Nirali N. Shah, Rimas J. Orentas et al. · Nature Medicine · 2017 · 1.3K citations

Life Sciences, Immunology, Oncology +14

Selumetinib in Children with Inoperable Plexiform Neurofibromas

Andrea M. Gross, Pamela L. Wolters, Eva Dombi et al. · New England Journal of Medicine · 2020 · 698 citations · Full text

Medicine, Neurology, Pediatrics +9

Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas

Eva Dombi, Andrea Baldwin, Leigh Marcus et al. · New England Journal of Medicine · 2016 · 665 citations · Full text

Medicine, Neurology, Oncology +16

Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory.

Danette Hann, Paul B. Jacobsen, Lora M. Azzarello et al. · Quality of Life Research · 1998 · 527 citations

Nursing, Oncology, Cancer Symptom Management +10

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

Nirali N. Shah, Steven L. Highfill, Haneen Shalabi et al. · Journal of Clinical Oncology · 2020 · 416 citations · Full text

Life Sciences, Hematology, Immunology +17